Cite
HARVARD Citation
Fukushima, T. et al. (2022). Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting. JGH open. 6 (1), pp. 29-35. [Online].